Cardiff Oncology, Inc.
For the period ended Jun 30, 2025. Filed Jul 29, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Jul 29, 2025
CRDF$0.79-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Stockholders’ Equity
| PreferredStockShares | PreferredStockAmount | CommonStockShares | CommonStockAmount | Additional Paid-InCapital | AccumulatedOtherComprehensiveGain | AccumulatedDeficit | TotalStockholders’Equity | |
|---|---|---|---|---|---|---|---|---|
| Balance, December 31, 2024 | 61 | $— | 66,524 | $7 | $467,087 | $34 | $(384,179) | $82,949 |
| Stock-based compensation | — | — | — | — | 1,365 | — | — | 1,365 |
| Issuance of common stock upon exercise of stock options | — | — | 2 | — | 3 | — | — | 3 |
| Other comprehensive loss | — | — | — | — | — | (7) | — | (7) |
| Net loss | — | — | — | — | — | — | (13,434) | (13,434) |
| Balance, March 31, 2025 | 61 | — | 66,526 | 7 | 468,455 | 27 | (397,613) | 70,876 |
| Stock-based compensation | — | — | — | — | 1,683 | — | — | 1,683 |
| Other comprehensive loss | — | — | — | — | — | (10) | — | (10) |
| Net loss | — | — | — | — | — | — | (13,943) | (13,943) |
| Balance, June 30, 2025 | 61 | $— | 66,526 | $7 | $470,138 | $17 | $(411,556) | $58,606 |
CONDENSED STATEMENTS OF STOCKHOLDERS’ EQUITY
| PreferredStockShares | PreferredStockAmount | CommonStockShares | CommonStockAmount | Additional Paid-InCapital | AccumulatedOtherComprehensiveLoss | AccumulatedDeficit | TotalStockholders’Equity | |
|---|---|---|---|---|---|---|---|---|
| Balance, December 31, 2023 | 61 | $— | 44,677 | $4 | $409,343 | $(67) | $(339,541) | $69,739 |
| Modified-retrospective adoption of ASU 2020-06 | — | — | — | — | (793) | — | 793 | — |
| Stock-based compensation | — | — | — | — | 1,124 | — | — | 1,124 |
| Issuance of common stock upon exercise of stock options | — | — | 33 | — | 107 | — | — | 107 |
| Other comprehensive loss | — | — | — | — | — | (65) | — | (65) |
| Net loss | — | — | — | — | — | — | (10,011) | (10,011) |
| Balance, March 31, 2024 | 61 | — | 44,710 | 4 | 409,781 | (132) | (348,759) | 60,894 |
| Issuance of common stock, net of expenses(1) | — | — | 792 | 1 | 1,804 | — | — | 1,805 |
| Stock-based compensation | — | — | — | — | 1,179 | — | — | 1,179 |
| Issuance of common stock upon exercise of stock options | — | — | 100 | — | 253 | — | — | 253 |
| Other comprehensive gain | — | — | — | — | — | 35 | — | 35 |
| Net loss | — | — | — | — | — | — | (11,778) | (11,778) |
| Balance, June 30, 2024 | 61 | $— | 45,602 | $5 | $413,017 | $(97) | $(360,537) | $52,388 |
(1) Net of expenses of $197,000.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.